DK1429800T3 - Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose - Google Patents

Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose

Info

Publication number
DK1429800T3
DK1429800T3 DK02788511T DK02788511T DK1429800T3 DK 1429800 T3 DK1429800 T3 DK 1429800T3 DK 02788511 T DK02788511 T DK 02788511T DK 02788511 T DK02788511 T DK 02788511T DK 1429800 T3 DK1429800 T3 DK 1429800T3
Authority
DK
Denmark
Prior art keywords
cop
vaccine
lateral sclerosis
amyotrophic lateral
treatment
Prior art date
Application number
DK02788511T
Other languages
Danish (da)
English (en)
Inventor
Michal Eisenbach-Schwartz
Esther Yoles
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK1429800T3 publication Critical patent/DK1429800T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK02788511T 2001-12-06 2002-12-05 Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose DK1429800T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06
PCT/IL2002/000979 WO2003047500A2 (fr) 2001-12-06 2002-12-05 Vaccin et methode de traitement de maladies du motoneurone

Publications (1)

Publication Number Publication Date
DK1429800T3 true DK1429800T3 (da) 2009-04-27

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02788511T DK1429800T3 (da) 2001-12-06 2002-12-05 Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose

Country Status (24)

Country Link
US (1) US7351686B2 (fr)
EP (1) EP1429800B1 (fr)
JP (1) JP4542339B2 (fr)
KR (1) KR20040081431A (fr)
CN (2) CN102151330B (fr)
AT (1) ATE422362T1 (fr)
AU (1) AU2002353486B2 (fr)
CA (1) CA2469092C (fr)
CY (1) CY1109044T1 (fr)
DE (1) DE60231131D1 (fr)
DK (1) DK1429800T3 (fr)
ES (1) ES2322566T3 (fr)
HK (1) HK1067043A1 (fr)
HU (1) HU228207B1 (fr)
IL (1) IL160105A0 (fr)
IS (1) IS2670B (fr)
MX (1) MXPA04005537A (fr)
NO (1) NO336231B1 (fr)
NZ (1) NZ533356A (fr)
PL (1) PL205469B1 (fr)
PT (1) PT1429800E (fr)
RU (1) RU2303996C2 (fr)
SI (1) SI1429800T1 (fr)
WO (1) WO2003047500A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
ATE548045T1 (de) * 2003-01-07 2012-03-15 Yeda Res & Dev Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung
EP1684797A1 (fr) 2003-11-12 2006-08-02 Yeda Research and Development Co. Ltd. Vaccin et procede pour traiter des maladies neurodegeneratives
JP4808631B2 (ja) 2003-12-09 2011-11-02 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 精神医学的障害の治療用のコポリマー１を含む方法及びワクチン
CA2558380A1 (fr) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Therapie de combinaison avec acetate de glatiramer et riluzole
WO2005120542A2 (fr) * 2004-05-07 2005-12-22 Peptimmune, Inc. Methodes de traitement de maladie a l'aide de copolymeres aleatoires
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
JP5241012B2 (ja) * 2005-07-15 2013-07-17 ノバルティス アーゲー Ｐａｍｐｓ、病原体関連分子パターン
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
WO2009040814A1 (fr) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Utilisation du copolymère 1 pour le traitement de la dystrophie musculaire
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
MX347871B (es) 2010-10-11 2017-05-16 Teva Pharmaceutical Ind Ltd * Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
EA201490749A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
US9861686B2 (en) * 2011-12-05 2018-01-09 Ben-Gurion University Of The Negev Research & Development Authority Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)
CA2907909A1 (fr) * 2012-03-26 2013-10-03 Neuroquest Ltd. Marqueurs cellulaires pour diagnostiquer la maladie d'alzheimer et la progression de la maladie d'alzheimer
WO2014037952A1 (fr) 2012-09-10 2014-03-13 Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science Thérapie d'immunomodulation individualisée pour des troubles neurodégénératifs, une lésion du snc et la démence liée à l'âge
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
SE505316C2 (sv) 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
US20030108528A1 (en) 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (fr) 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Lymphocytes t actives, antigenes specifiques du systeme nerveux et leur utilisation
JP2002500199A (ja) 1998-07-21 2002-01-08 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 活性化ｔ細胞、及びそれらの用途
WO2000005249A2 (fr) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
ES2243450T3 (es) * 2000-01-20 2005-12-01 Yeda Research And Development Co. Ltd. El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para terapia neuroprotectora.
US20020037848A1 (en) * 2000-06-07 2002-03-28 Michal Eisenbach-Schwartz Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
WO2002076503A1 (fr) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy

Also Published As

Publication number Publication date
WO2003047500A2 (fr) 2003-06-12
CA2469092C (fr) 2013-02-19
EP1429800B1 (fr) 2009-02-11
AU2002353486A1 (en) 2003-06-17
PT1429800E (pt) 2009-04-27
CN1617736A (zh) 2005-05-18
CY1109044T1 (el) 2014-07-02
AU2002353486B2 (en) 2009-01-15
PL370070A1 (en) 2005-05-16
JP4542339B2 (ja) 2010-09-15
NO336231B1 (no) 2015-06-22
HUP0500039A3 (en) 2010-01-28
KR20040081431A (ko) 2004-09-21
SI1429800T1 (sl) 2009-08-31
CA2469092A1 (fr) 2003-06-12
WO2003047500A3 (fr) 2004-03-18
CN102151330A (zh) 2011-08-17
IL160105A0 (en) 2004-06-20
US7351686B2 (en) 2008-04-01
MXPA04005537A (es) 2004-11-01
IS2670B (is) 2010-09-15
EP1429800A2 (fr) 2004-06-23
US20050220802A1 (en) 2005-10-06
HU228207B1 (hu) 2013-01-28
JP2005515198A (ja) 2005-05-26
ES2322566T3 (es) 2009-06-23
NZ533356A (en) 2006-10-27
NO20042833L (no) 2004-08-12
HUP0500039A2 (hu) 2005-03-29
PL205469B1 (pl) 2010-04-30
CN102151330B (zh) 2017-04-12
EP1429800A4 (fr) 2006-03-22
RU2004120536A (ru) 2005-03-27
DE60231131D1 (de) 2009-03-26
HK1067043A1 (en) 2005-04-01
RU2303996C2 (ru) 2007-08-10
ATE422362T1 (de) 2009-02-15
IS7296A (is) 2004-06-03

Similar Documents

Publication Publication Date Title
DK1429800T3 (da) Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose
ATE455561T1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
NO20035740L (no) Fremgangsmater for a indusere en cytotoksisk immunrespons og rekombinante ape-adenovirussammensetninger nyttige for disse
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
DE60233898D1 (de) Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin-plasmaspiegeln
BR0109027A (pt) Peptìdios derivados de caseìna e usos dos mesmos em terapia
ATE504308T1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
MA28149A1 (fr) Compositions de vaccin comprenant une interleukine 18 et un systeme adjuvant de type saponine
MXPA05002814A (es) Formulacion para agentes lipofilicos.
BR9916857A (pt) 4 heteroaril diarilaminas
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
EA201000386A1 (ru) Нетоксичные для нервной ткани плазминоген-активирующие факторы для лечения инсульта
UY27373A1 (es) Formulaciones de interferón beta-humano
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
HUP0500642A2 (hu) Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra
EP1370697A4 (fr) Medicaments a base de peroxyredoxine pour le traitement d'infections par le vih-1, et leurs methodes d'utilisation
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada
RU2350351C2 (ru) Композиции и лекарственные формы на основе гастрина, методы применения и получения
ES2195861T3 (es) Uso de (ir,4s)-4-(6-amino-9h-purin-9-il)-2-ciclopenten-1-metanol en vhb.
SE9902674D0 (sv) New composition
HRP20030701A2 (en) Natural antibodies active against hiv virus
IT1276453B1 (it) Vaccino/composizioni terapautica di helycobacter pylori, loro preparazione ed impiego.